Aldosterone is an important driver of inflammation and fibrosis leading to renal and cardiovascular complications. MRA lower albuminuria but data showing prevention of end-stage kidney disease are lacking. Side effects including hyperkalemia have previously prevented long-term studies in diabetic kidney disease but new treatment strategies with potassium binders, aldosterone synthase inhibitors and nonsteroidal MRA have been developed for clinical testing.
Authors: Frimodt-Møller, Mariea; Persson, Frederika; Rossing, Petera
Keywords: diabetic kidney disease, aldosterone synthase inhibitors, nonsteroidal mineralocorticoid receptor antagonist
DOI Number: 10.1097/MNH.0000000000000557 Publication Year: 2020
To search for other research papers by topic, keyword, author, or year, please go to our Publications page.